Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine

作者：Jiangtao Lin, Jiansan Zhang, Nan Su, Jianguo Xu, Nan Wang, Jiang-Ting Chen, Xin Chen, Yuxuan Liu, Hong Gao, Yuping Jia, Yan Liu, Ruihua Sun, Xu Wang, Dongzheng Yu, Rong Hai, Qiang Gao, Ning Ye, Hongxia Wang, Machao Li, Biao Kan, Dong Guan-mu, Qi An, Ying-Qun Wang, Jun Han, Chuan Qin, Weidong Yin, Xiao‐Ping Dong · 发表于：Antiviral Therapy · 年份：2007 · DOI：10.1177/135965350701200702 · 被引用次数：170 · 研究领域：SARS-CoV-2 and COVID-19 Research、vaccines and immunoinformatics approaches、COVID-19 Clinical Research Studies

BACKGROUND: Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health. METHODS: To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control. RESULTS: On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later. CONCLUSION: The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.